At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
Margetuximab 10 mg/kg +2 morebiological
Likely dose
Margetuximab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
In Brief
A Phase 2 clinical trial evaluating Margetuximab 10 mg/kg, Margetuximab 15 mg, and 1 other intervention for Gastric Cancer and 2 related conditions. Completed, enrolled 95 participants across 28 sites in 5 countries.
Detailed Summary
This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Stomach Cancer, Esophageal Cancer
CountriesCanada, Singapore, South Korea, Taiwan, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedFeb 2016
Primary CompletionJan 2021
TodayJul 2026
First PostedFeb 23, 2016
Enrollment StartJan 1, 2016
Primary CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 10.4 years ago
Interventions
Margetuximab 10 mg/kgbiological
Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
Margetuximab 15 mgbiological
Margetuximab treatment is administered IV once every 21-day cycle
Pembrolizumabbiological
Pembrolizumab treatment is administered IV once every 21-day cycle